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 Aptamers in therapy 






• Spiegeman and his colleagues publish their work with nucleic acid in 
1960. 
• The result was the invention of PCR in 1986 by Molis.
• In 1990  SELEX  (Selective expansion of ligands by exponential 
enrichment) were invented.
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 Aptamers ( By Ellington) are oligonucleotides
 (DNA or RNA) that can bind with high affinity 
 specificity to a wide range of target molecules 
such as drugs, proteins or other organic or in 
organic molecules 
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Aptamers, derived from the Latin 
aptus,meaning ‘‘to fit”
• Each RNA molecules have specific sequences of nucleic acids.
• These molecules bind to different positions 
• Establish hydrogen bonds and van der Waals molecules 
• These RNA are called  Aptamer and the  binding site are




Affinity Low nM to pM Low nM to pM
Specificity High High
Production In Vitro Chemical 
Process
In Vivo Biological 
Systems
Target Range* Wide: Ions, Cell, Toxins Narrow: Immunogenics
Batch to Batch 
Variation
Little or No Significant
Chemical Modification* Easy Limited
Thermal Denaturation Reversible Irreversible
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Aptamers: Denser immobilization on the surface
Aptamers: Nuclease sensitive
Creation of Aptamers
• Aptamers are generated by an iterative selection process, called 
systematic evolution of ligands by exponential enrichment (SELEX). 
• SELEX technology have extended aptamer selection from 
comparatively simple mixtures of purified proteins to whole living 
cells.
• SELEX isolate Aptamers that bind to specific target cells.
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SELEX
 SELEX is a multi-step process in which strongly bind
 ligands are preferably selected by rounds of affinity assays and PCR
amplification
 The SELEX method has permitted the identification of unique RNA/DNA 
molecules which bind to the target with very high affinity and specificity
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• A sensor is a device that transforms environmental information, ranging from
the concentration of a specific sample component to total 














Essential Factors for 
Biosensors Operation 
• Sensitivity to presence of target
• The fabricated biosensor should show sensitivity to the presence of its 
own target. 
• Linearity  of response




• Chemicals interference must be minimized for obtaining the correct 
result.
• Reproducibility




• Using affinity surfaces
• Using affinity tags
• Using column matrices or ligands
• Nitrocellulose membrane filtration
• Cross-linking
• Antibody-based






• Affinity surfaces: allow proteins and small molecules to bind with 
them & have affinities with RNA or DNA.
• Magnetic beads, affinity titer plates





•Incubating the pool 
RNA with the BSA-
coated beads in binding 
buffer for 10 min.
Step 3
Counter selection
•The unbound RNA was 
collected with the help of 
magnet and applied onto 
beads coated with the same 
subtype A/Aichi virus as the 
counter-selection to remove 
molecules specific to A/Aichi.
•Incubating for 10 min.
STEP4
selection
•The unbound molecules were again 
collected and incubated with beads 
coated with the target A/Panama virus
•After this incubation, the beads were 
washed three times with 300 μl of 
binding buffer. 
•Bound RNAs were recovered with a 
hot 7M urea solution.









•Coating the whole virus onto 
beads
•BSA Blocking
•Washing the coated beads.
•Denaturing the pool RNA(90 °C 
for 2 min and allowed to cool at 
room temperature for 10 min)
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Using capillary electrophoresis
• The nucleic acid sequences that bind the target undergo a mobility shift.
• no need to wash the active sequences off a column as in conventional 
SELEX, eliminating any kinetic bias.










APTAMER TO THERAPEUTIC TARGET 
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APTAMER TO THERAPEUTIC TARGET 
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Aptamer and Epidermal growth factor receptor 
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• Epidermal growth factor receptor (EGFR/HER1/c-ErbB1), is 
overexpressed in many solid cancers.
• TuTu22 aptamer was able to recognize cancer cells expressing EGFR 
but did not bind to the EGFR-negative cells. 
• This DNA aptamers will facilitate the development of novel targeted 




 In vitro and in vivo diagnostic tools








 The first aptamer to a nucleotide was isolated in 1993 by Sassanfar and 
Szostak
 In 2004 RNA selection   aptamers that recognized the triphosphate of 
ATP were selected in the laboratory of Jack W. Szostak (Sazani et al., 2004)
 Interact with the part of the target molecule that faced the matrix, but 
did not strongly interact with the part that had greatest accessibility.  
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Analytic Detection:Aptamers to Nucleic Acid
Conclusion  
• Aptamer technology has made significant strides.
• Aptamers can be applied to many fields of molecular medicine
• The identification of aptamer molecular targets constitutes a novel 
method of biomarker discovery
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• Cell-specific aptamers can be readily adapted for drug delivery and 
targeted therapy
• Cell-SELEX represents an integrated technology that will revolutionize 
the way we diagnose, treat and prevent disease
• represents an integrated technology that will revolutionize the way 
we diagnose, treat and revent disease.
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Research Perspectives
Aptamers are the very astonish way to diagnose  and  diagnosis 
disease 
It seems using Aptamer will help us one step closer to understanding 
all sort of sickness especially  in cancer world
Limitation and weakness point of this knowledge is still under 
observation
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